ABSTRACT
Background Metformin is a pharmacological candidate to mitigate second-generation antipsychotic (SGA)-induced weight gain in patients with severe mental illnesses (SMI).
Objective To evaluate the incidence, prevalence, and demographic patterns of metformin co-prescription among patients diagnosed with SMI initiating SGAs. To estimate the impact of co-prescription on weight.
Methods A cohort study of patients diagnosed with SMI initiating aripiprazole, olanzapine, quetiapine, or risperidone in 2005-2019 using primary care data from Clinical Practice Research Datalink. We estimated cumulative incidence and period prevalences of co-prescription and explored prescribing differences by demographic and clinical factors. We compared weight change among patients prescribed an SGA only versus an SGA plus metformin, accounting for confounders using linear regression.
Findings Among 26,537 patients initiating SGAs, 4652 were ever prescribed metformin and 21,885 were not. Two-year incidence of first metformin prescription was 3.3%. The SGA plus metformin group were more ethnically diverse, had greater social deprivation, more comorbidities, and higher baseline weight (mean 90.4 vs. 76.8 kg). By two years post-SGA initiation, mean weight in the SGA- only group had changed by +4.16% (95% CI, -1.26 to +9.58) compared to -0.65% (95% CI, -4.26 to +2.96) in the SGA plus metformin group. After confounder adjustment, the two-year mean difference in weight with metformin co-prescription was -1.48 kg (95% CI, -4.03 to 1.07) among females and -1.84 kg (95% CI, -4.67 to 0.98) among males.
Conclusion Metformin is infrequently co-prescribed, despite established efficacy and guidelines.
Clinical implications Primary and secondary care collaboration should be strengthened and barriers to co-prescribing addressed.
Competing Interest Statement
JFH has received consultancy fees from Wellcome Trust and funding grants from juli Health. All other authors declare no potential competing interests.
Funding Statement
ARB is funded by the Wellcome Trust through a PhD Fellowship in Mental Health Science. This research was funded in whole or in part by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript (AAM) version arising from this submission. DPJO is supported by the University College London Hospitals NIHR Biomedical Research Centre and the NIHR North Thames Applied Research Collaboration. This funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. JFH is supported by UKRI grant MR/V023373/1, the University College London Hospitals NIHR Biomedical Research Centre and the NIHR ARC North Thames. NMD is supported via a Norwegian Research Council 295989 and the UCL Division of Psychiatry. LFT is supported by NHS England. NL is supported by a HDR UK personal fellowship (Big Data for Complex Disease- HDR-23012). This work is affiliated to HDR UK which is funded by the Medical Research Council (UKRI), the National Institute for Health Research, the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council (UKRI), the Engineering and Physical Sciences Research Council (UKRI), Health and Care Research Wales, Chief Scientist Office of the Scottish Government Health and Social Care Directorates, and Health and Social Care Research and Development Division (Public Health Agency, Northern Ireland).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Independent Scientific Advisory Committee of CPRD (protocol no. 21_000729).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data was accessed via Clinical Practice Research Datalink (CPRD) under approved protocol no. 21_000729. Authors cannot share the data directly. However, data can be accessed directly from Clinical Practice Research Datalink (CPRD) following approval and licensing
https://github.com/Alvin-RB/antipsychotic_metformin_coprescription